Skip to main content
. 2016 Feb 23;7(13):16248–16261. doi: 10.18632/oncotarget.7637

Figure 6. BRD7 suppresses the tumorigenicity of HCC in vivo.

Figure 6

A. The tumor growth curves for each group are shown. BRD7 overexpression markedly reduced the tumor growth rate of HCC in vivo. B. Photographs of dissected tumors from the nude mice. The final tumor volumes were much smaller in the Bel7402/LV-BRD7 and Hep3B/LV-BRD7 transfection groups compared with the Bel7402/LV-NC and Hep3B/LV-NC transfection groups. C. The tumor weights of each group are shown. The final tumor weights were lower in the tumors that overexpressed BRD7. The data are presented as the means ± SD. P-values were calculated using the independent Student's t-test. *, P < 0.05 versus LV-Vector; ***, P < 0.001 versus LV-Vector.